Cargando…
In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations
INTRODUCTION: The atypical antipsychotic olanzapine is approved for the treatment of schizophrenia and bipolar I disorder; however, weight gain and metabolic dysregulation associated with olanzapine therapy have limited its clinical utility. In clinical studies, treatment with the combination of ola...
Autores principales: | Tan, Laura A, Gajipara, Nileshkumar, Sun, Lei, Bacolod, Maria, Zhou, Ying, Namchuk, Mark, Cunningham, Jacobi I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636859/ https://www.ncbi.nlm.nih.gov/pubmed/36345421 http://dx.doi.org/10.2147/NDT.S373195 |
Ejemplares similares
-
Samidorphan mitigates olanzapine-induced weight gain and metabolic
dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019) -
A Review of Samidorphan: A Novel Opioid Antagonist
por: Chaudhary, Amna Mohyud Din, et al.
Publicado: (2019) -
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021) -
Naltrexone Implant for Opioid Use Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021) -
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies
por: Fava, Maurizio, et al.
Publicado: (2018)